Prevention and treatment of knee osteoarthritis by natural products: potential mechanisms based on articular cartilage targets

Abstract

Knee osteoarthritis (KOA) is a prevalent chronic degenerative joint disorder characterized by an imbalance between articular cartilage degradation and synthesis, a central mechanism in KOA pathogenesis. Given the absence of disease-modifying therapies, there is a critical need to elucidate the underlying pathological processes, establish reliable biomarkers for early detection and prognosis, and identify safer, more effective therapeutic agents. In recent years, natural products have attracted considerable interest due to their low toxicity, cost-effectiveness, and distinct biological activities, demonstrating significant potential in KOA management. These compounds can impede KOA progression through multiple mechanisms, including promoting cartilage matrix synthesis, mitigating inflammation, reducing oxidative stress, suppressing chondrocyte apoptosis, and modulating autophagy, thereby supporting their translational application. This review summarizes biomarkers relevant to early diagnosis and phenotypic stratification in KOA, with a focus on elucidating the pharmacological actions and molecular mechanisms of natural products, such as flavonoids, alkaloids, saponins, terpenes, and traditional Chinese medicine (TCM) formulas, in KOA intervention, aiming to provide evidence-based strategies for improved disease management.

Keywords

Knee osteoarthritis / Cartilage / Natural products / Pharmacotherapies / Biomarkers

Funding

This work was supported by the National Science Foundation of China (No. 82474144), and the Zhejiang Province Technological Leading Talents Fund Project (No. 2022R52031).

Supporting information

Supporting information for this work can be obtained by contacting the corresponding authors via E-mail.

Declaration of competing interest

These authors have no conflict of interest to declare.

References

[1] Courties A, Kouki I, Soliman N, et al. Osteoarthritis year in review 2024: epidemiology and therapy. Osteoarthritis Cartilage. 2024; 32(11):1397-1404. https://doi.org/10.1016/j.joca.2024.07.014.

[2] GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol2023; 5(9):e508-e522. https://doi.org/10.1016/S2665-9913(23)00163-7.

[3] Siddiq MAB, Oo WM, Hunter DJ.New therapeutic strategies in osteoarthritis. Joint Bone Spine. 2024; 91(6):105739. https://doi.org/10.1016/j.jbspin.2024.105739.

[4] Fujii Y, Liu L, Yagasaki L, et al. Cartilage homeostasis and osteoarthritis. Int J Mol Sci. 2022; 23(11):6316. https://doi.org/10.3390/ijms23116316.

[5] Sun Q, Zhang YZ, Ding YL, et al. Inhibition of PGE2 in subchondral bone attenuates osteoarthritis. Cells. 2022; 11(17):2760. https://doi.org/10.3390/cells11172760.

[6] Muthu S, Korpershoek JV, Novais EJ, et al. Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies. Nat Rev Rheumatol. 2023; 19(7):403-416. https://doi.org/10.1038/s41584-023-00979-5.

[7] Yao Q, Wu XH, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1):56. https://doi.org/10.1038/s41392-023-01330-w.

[8] Jang S, Lee K, Ju JH. Recent updates of diagnosis, pathophysiology, and treatment on osteoarthritis of the knee. Int J Mol Sci. 2021; 22(5):2619. https://doi.org/10.3390/ijms22052619.

[9] Pereira TV, Jüni P, Saadat P, et al. Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis. BMJ. 2022; 378:e069722. https://doi.org/10.1136/bmj-2022-069722.

[10] Zhang MD, Wang ZQ, Ding CH. Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies. Expert Opin Pharmacother. 2024; 25(9):1209-1227. https://doi.org/10.1080/14656566.2024.2374464.

[11] Maouche A, Boumediene K, Baugé C. Bioactive compounds in osteoarthritis: molecular mechanisms and therapeutic roles. Int J Mol Sci. 2024; 25(21):11656. https://doi.org/10.3390/ijms252111656.

[12] Yu Y, Ma TW, Lv LY, et al. Oleanolic acid targets the regulation of PI3K/AKT/mTOR pathway and activates autophagy in chondrocytes to improve osteoarthritis in rats. J Funct Foods. 2022; 94:105144. https://doi.org/10.1016/j.jff.2022.105144.

[13] Li YT, Ding ZF, Liu FE, et al. Luteolin regulating synthesis and catabolism of osteoarthritis chondrocytes via activating autophagy. Heliyon. 2024; 10(11):e31028. https://doi.org/10.1016/j.heliyon.2024.e31028.

[14] Qin HN, Liu XJ, Ding QR, et al. Astaxanthin reduces inflammation and promotes a chondrogenic phenotype by upregulating SIRT1 in osteoarthritis. Knee. 2024; 48:83-93. https://doi.org/10.1016/j.knee.2024.03.002.

[15] Pérez-Lozano ML, Cesaro A, Mazor M, et al. Emerging natural-product-based treatments for the management of osteoarthritis. Antioxidants (Basel). 2021; 10(2):265. https://doi.org/10.3390/antiox10020265.

[16] Peng Z, Sun H, Bunpetch V, et al. The regulation of cartilage extracellular matrix homeostasis in articular cartilage degeneration and regeneration. Biomaterials. 2021; 268:120555. https://doi.org/10.1016/j.biomaterials.2020.120555.

[17] Ouyang ZW, Dong L, Yao F, et al. Cartilage-related collagens in osteoarthritis and rheumatoid arthritis: from pathogenesis to therapeutics. Int J Mol Sci. 2023; 24(12):9841. https://doi.org/10.3390/ijms24129841.

[18] Goldring SR, Goldring MB. Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage-bone crosstalk. Nat Rev Rheumatol. 2016; 12(11):632-644. https://doi.org/10.1038/nrrheum.2016.148.

[19] Chow YY, Chin KY. The role of inflammation in the pathogenesis of osteoarthritis. Mediators Inflamm. 2020; 2020:8293921. https://doi.org/10.1155/2020/8293921.

[20] Zhou SH, Thornhill TS, Meng FG, et al. Influence of osteoarthritis grade on molecular signature of human cartilage. J Orthop Res. 2016; 34(3):454-462. https://doi.org/10.1002/jor.23043.

[21] Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019; 393(10182):1745-1759. https://doi.org/10.1016/S0140-6736(19)30417-9.

[22] Mukherjee A, Das B. The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis. Biomater Biosyst. 2024; 13:100090. https://doi.org/10.1016/j.bbiosy.2024.100090.

[23] Pulik Ł, Łęgosz P, Motyl G. Matrix metalloproteinases in rheumatoid arthritis and osteoarthritis: a state of the art review. Reumatologia. 2023; 61(3):191-201. https://doi.org/10.5114/reum/168503.

[24] Li T, Peng J, Li QQ, et al. The mechanism and role of ADAMTS protein family in osteoarthritis. Biomolecules. 2022; 12(7):959. https://doi.org/10.3390/biom12070959.

[25] Bay-Jensen AC, Engstroem A, Sharma N, et al. Blood and urinary collagen markers in osteoarthritis: markers of tissue turnover and disease activity. Expert Rev Mol Diagn. 2020; 20(1):57-68. https://doi.org/10.1080/14737159.2020.1704257.

[26] Alcaide-Ruggiero L, Molina-Hernández V, Granados MM, et al. Main and minor types of collagens in the articular cartilage: the role of collagens in repair tissue evaluation in chondral defects. Int J Mol Sci. 2021; 22(24):13329. https://doi.org/10.3390/ijms222413329.

[27] Bourgot I, Primac I, Louis T, et al. Reciprocal interplay between fibrillar collagens and collagen-binding integrins: implications in cancer progression and metastasis. Front Oncol. 2020; 10:1488. https://doi.org/10.3389/fonc.2020.01488.

[28] Bielajew BJ, Hu JC, Athanasiou KA. Collagen: quantification, biomechanics, and role of minor subtypes in cartilage. Nat Rev Mater. 2020; 5(10):730-747. https://doi.org/10.1038/s41578-020-0213-1.

[29] Radojčić MR, Thudium CS, Henriksen K, et al. Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients. Pain. 2017; 158(7):1254-1263. https://doi.org/10.1097/j.pain.0000000000000908.

[30] van de Stadt LA, Kroon FPB, Thudium CF, et al. Serum biomarkers in prednisolone-treated hand osteoarthritis patients. Rheumatology (Oxford). 2023; 62(3):1350-1355. https://doi.org/10.1093/rheumatology/keac442.

[31] Kjelgaard-Petersen C, Siebuhr AS, Christiansen T, et al. Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis. Biomarkers. 2015; 20(8):547-556. https://doi.org/10.3109/1354750X.2015.1105497.

[32] Loeser RF, Beavers DP, Bay-Jensen AC, et al. Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis: the intensive diet and exercise for arthritis trial (IDEA). Osteoarthritis Cartilage. 2017; 25(11):1822-1828. https://doi.org/10.1016/j.joca.2017.07.015.

[33] Siebuhr AS, Petersen KK, Arendt-Nielsen L, et al. Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. Osteoarthritis Cartilage. 2014; 22(1):44-50. https://doi.org/10.1016/j.joca.2013.10.020.

[34] Rapp AE, Zaucke F. Cartilage extracellular matrix-derived matrikines in osteoarthritis. Am J Physiol Cell Physiol. 2023; 324(2):C377-C394. https://doi.org/10.1152/ajpcell.00464.2022.

[35] Kalogera S, Jansen MP, Bay-Jensen AC, et al. Relevance of biomarkers in serum vs. synovial fluid in patients with knee osteoarthritis. Int J Mol Sci. 2023; 24(11):9483. https://doi.org/10.3390/ijms24119483.

[36] Bjerre-Bastos JJ, Sejersen C, Nielsen HB, et al. The impact of weight-bearing exercise, non-weight-bearing exercise, and cardiovascular stress on biochemical markers of cartilage turnover in patients with mild to moderate knee osteoarthritis: a sequential, cross-over, clinical study. Cartilage. 2025; 162(2):159-168. https://doi.org/10.1177/19476035241258170.

[37] Papaneophytou C, Alabajos-Cea A, Viosca-Herrero E, et al. Associations between serum biomarkers of cartilage metabolism and serum hyaluronic acid, with risk factors, pain categories, and disease severity in knee osteoarthritis: a pilot study. BMC Musculoskelet Disord. 2022; 23(1):195. https://doi.org/10.1186/s12891-022-05133-y.

[38] Bay-Jensen AC, Mobasheri A, Thudium CS, et al. Blood and urine biomarkers in osteoarthritis: an update on cartilage associated type II collagen and aggrecan markers. Curr Opin Rheumatol. 2022; 34(1):54-60. https://doi.org/10.1097/BOR.0000000000000845.

[39] Huang MJ, Zhao JY, Huang Y, et al. Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis. J Orthop Translat. 2017; 13:50-57. https://doi.org/10.1016/j.jot.2017.06.005.

[40] Selistre LFA, Gonçalves GH, Vasilceac FA, et al. The relationship between urinary C-telopeptide fragments of type II collagen, knee joint load, pain, and physical function in individuals with medial knee osteoarthritis. Braz J Phys Ther. 2020; 25(1):62-69. https://doi.org/10.1016/j.bjpt.2020.02.002.

[41] García-Alvarado FJ, González-Martínez MDR, Jaramillo-Rodríguez Y, et al. Increased urinary concentration of C-terminal telopeptide of type II collagen and pain by radiographic grade in women with knee osteoarthritis in northeastern mexico: a cross-sectional study. Biores Open Access. 2020; 9(1):7-12. https://doi.org/10.1089/biores.2019.0003.

[42] Krawetz RJ, Wu YE, Bertram KL, et al. Synovial mesenchymal progenitor derived aggrecan regulates cartilage homeostasis and endogenous repair capacity. Cell Death Dis. 2022; 13(5):470. https://doi.org/10.1038/s41419-022-04919-1.

[43] Hagemans FJA, Larsson S, Reijman M, et al. An anterior cruciate ligament rupture increases levels of urine N-terminal cross-linked telopeptide of type I collagen, urine C-terminal cross-linked telopeptide of type II collagen, serum aggrecan ARGS neoepitope, and serum tumor necrosis factor-α. Am J Sports Med. 2021; 49(13):3534-3543. https://doi.org/10.1177/03635465211042310.

[44] Larsson S, Englund M, Struglics A, et al. Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis. Arthritis Res Ther. 2010; 12(6):R230. https://doi.org/10.1186/ar3217.

[45] Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021; 325(6):568-578. https://doi.org/10.1001/jama.2020.22171.

[46] Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage. 2023; 31(4):458-466. https://doi.org/10.1016/j.joca.2022.11.005.

[47] Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020; 17(9):574-584. https://doi.org/10.1038/s41569-020-0366-z.

[48] D'Arcy Y, Mantyh P, Yaksh T, et al. Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies. Postgrad Med. 2021; 133(8):879-894. https://doi.org/10.1080/00325481.2021.1949199.

[49] Mintarjo JA, Poerwanto E, Tedyanto EH. Current non-surgical management of knee osteoarthritis. Cureus. 2023; 15(6):e40966. https://doi.org/10.7759/cureus.40966.

[50] Yilmaz E. The evaluation of the effectiveness of intra-articular steroid, tenoxicam, and combined steroid-tenoxicam injections in the treatment of patients with knee osteoarthritis. Clin Rheumatol. 2019; 38(11):3243-3252. https://doi.org/10.1007/s10067-019-04641-y.

[51] Honvo G, Reginster JY, Rannou F, et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019; 36(Suppl 1):101-127. https://doi.org/10.1007/s40266-019-00657-w.

[52] Hummer CD, Angst F, Ngai W, et al. High molecular weight Intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis. BMC Musculoskelet Disord. 2020; 21(1):702. https://doi.org/10.1186/s12891-020-03729-w.

[53] Chen Y, Xue Y, Wang XZ, et al. Molecular mechanisms of the Guizhi decoction on osteoarthritis based on an integrated network pharmacology and RNA sequencing approach with experimental validation. Front Genet. 2023; 14:1079631. https://doi.org/10.3389/fgene.2023.1079631.

[54] Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014; 9:451-458. https://doi.org/10.2147/CIA.S58535.

[55] Henrotin Y, Gharbi M, Dierckxsens Y, et al. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med. 2014; 14:159. https://doi.org/10.1186/1472-6882-14-159.

[56] Leung YY, Haaland B, Huebner JL, et al. Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Osteoarthritis Cartilage. 2018; 26(5):631-640. https://doi.org/10.1016/j.joca.2018.01.026.

[57] Lao L, Hochberg M, Lee DYW, et al. Huo-Luo-Xiao-Ling (HLXL)-Dan, a traditional Chinese medicine, for patients with osteoarthritis of the knee: a multi-site, randomized, double-blind, placebo-controlled phase II clinical trial. Osteoarthritis Cartilage. 2015; 23(12):2102-2108. https://doi.org/10.1016/j.joca.2015.06.007.

[58] Henrotin Y, Cozannet RL, Fança-Berthon P, et al. Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial. BMC Musculoskelet Disord. 2022; 23(1):650. https://doi.org/10.1186/s12891-022-05612-2.

[59] Zhou GH, Zhang XQ, Gu ZX, et al. Research progress on the treatment of knee osteoarthritis combined with osteoporosis by single-herb Chinese medicine and compound. Front Med (Lausanne). 2023; 10:1254086. https://doi.org/10.3389/fmed.2023.1254086.

[60] Zhou GH, Zhang XQ, Gu ZX, et al. Research progress in single-herb Chinese medicine and compound medicine for knee osteoarthritis. Comb Chem High Throughput Screen. 2024; 27(15):2180-2186. https://doi.org/10.2174/0113862073264850231116055745.

[61] Tong X, Wang Y, Dong BC, et al. Effects of genus Epimedium in the treatment of osteoarthritis and relevant signaling pathways. Chin Med. 2023; 18(1):92. https://doi.org/10.1186/s13020-023-00788-8.

[62] Wu SS, Hao LJ, Shi YY, et al. Network pharmacology-based analysis on the effects and mechanism of the Wang-Bi Capsule for rheumatoid arthritis and osteoarthritis. ACS Omega. 2022; 7(9):7825-7836. https://doi.org/10.1021/acsomega.1c06729.

[63] Sun Q, Jin HT, Li WY, et al. Study of the curative effect of Zhang's Xibi formula and its underlying mechanism involving inhibition of inflammatory responses and delay of knee osteoarthritis. J Orthop Surg Res. 2023; 18(1):963. https://doi.org/10.1186/s13018-023-04453-6.

[64] Tan X, Zheng DH, Lin Q, et al. Confirmation of pain-related neuromodulation mechanism of Bushen Zhuangjin Decoction on knee osteoarthritis. J Ethnopharmacol. 2024; 324:117772. https://doi.org/10.1016/j.jep.2024.117772.

[65] Wu CZ, Ge QW, Shi ZY, et al. Elucidation of the underlying mechanism of Gujian Oral Liquid acting on osteoarthritis through network pharmacology, molecular docking, and experiment. Biomed Res Int. 2022; 2022:9230784. https://doi.org/10.1155/2022/9230784.

[66] Jia ZY, Zhang JL, Yang XT, et al. Bioactive components and potential mechanisms of Biqi Capsule in the treatment of osteoarthritis: based on chondroprotective and anti-inflammatory activity. Front Pharmacol. 2024; 15:1347970. https://doi.org/10.3389/fphar.2024.1347970.

[67] Jiang Z, Yao XL, Ma WK, et al. Molecular mechanism analysis of Miao medicine Jinwujiangu Decoction in treating osteoarthritis based on a network pharmacology approach. J Tradit Chin Med. 2022; 42(4):576-585. https://doi.org/10.19852/j.cnki.jtcm.20220519.002.

[68] Lee SG, Kang H. Protective effects of a mixed medicinal herb extract (NUC1) on collagenase-induced osteoarthritis in rabbits. J Microbiol Biotechnol. 2023; 33(11):1484-1494. https://doi.org/10.4014/jmb.2303.03044.

[69] Li XH, Zhang ZL, Liang WN, et al. Tougu Xiaotong Capsules may inhibit p38 MAPK pathway-mediated inflammation: in vivo and in vitro verification. J Ethnopharmacol. 2020; 249:112390. https://doi.org/10.1016/j.jep.2019.112390.

[70] Wu JF, Li WX, Ye BQ, et al. The efficacy and safety of Xianling Gubao Capsules in the treatment of knee osteoarthritis: a protocol for a randomized, double-blind, controlled trial. Medicine (Baltimore). 2021; 100(36):e27086. https://doi.org/10.1097/MD.0000000000027086.

[71] Zhu YY, Zhong WL, Peng J, et al. Study on the mechanism of Baimai Ointment in the treatment of osteoarthritis based on network pharmacology and molecular docking with experimental verification. Front Genet. 2021; 12:750681. https://doi.org/10.3389/fgene.2021.750681.

[72] Jia T, Qiao JT, Guan DH, et al. Anti-inflammatory effects of licochalcone A on IL-1β-stimulated human osteoarthritis chondrocytes. Inflammation. 2017; 40(6):1894-1902. https://doi.org/10.1007/s10753-017-0630-5.

[73] Ji BC, Zhang ZD, Guo WT, et al. Isoliquiritigenin blunts osteoarthritis by inhibition of bone resorption and angiogenesis in subchondral bone. Sci Rep. 2018; 8(1):1721. https://doi.org/10.1038/s41598-018-19162-y.

[74] Li Q, Xu JY, Hu X, et al. The protective effects and mechanism of Ruyi Zhenbao Pill, a Tibetan medicinal compound, in a rat model of osteoarthritis. J Ethnopharmacol. 2023; 308:116255. https://doi.org/10.1016/j.jep.2023.116255.

[75] Gao HW, Wang XK, Luo ZJ, et al. Clinical study of bone hyperplasia pain pill combined with acupuncture for knee osteoarthritis. J Chin Arch Tradit Chin Med. 2019; 37:710-713. https://doi.org/10.13193/j.issn.1673-7717.2019.03.048.

[76] Yang J, Zhou ZW, Ding XL, et al. Gubi Zhitong Formula alleviates osteoarthritis in vitro and in vivo via regulating BNIP3L-mediated mitophagy. Phytomedicine. 2024; 128:155279. https://doi.org/10.1016/j.phymed.2023.155279.

[77] Wang KL, Lu XY, Li XY, et al. Dual protective role of velutin against articular cartilage degeneration and subchondral bone loss via the p 38 signaling pathway in murine osteoarthritis. Front Endocrinoln (Lausanne). 2022; 13:926934. https://doi.org/10.3389/fendo.2022.926934.

[78] Fan Y, Yin L, Zhong XG, et al. An integrated network pharmacology, molecular docking and experiment validation study to investigate the potential mechanism of isobavachalcone in the treatment of osteoarthritis. J Ethnopharmacol. 2024; 326:117827. https://doi.org/10.1016/j.jep.2024.117827.

[79] Wang Y, Li ZZ, Wang B, et al. Naringenin attenuates inflammation and apoptosis of osteoarthritic chondrocytes via the TLR4/TRAF6/NF-κB pathway. PeerJ. 2023; 11:e16307. https://doi.org/10.7717/peerj.16307.

[80] Cai WX, Zhang YB, Jin WY, et al. Procyanidin B2 ameliorates the progression of osteoarthritis: an in vitro and in vivo study. Int Immunopharmacol. 2022;113(Pt A):109336. https://doi.org/10.1016/j.intimp.2022.109336.

[81] Yang H, Wang ZT, Wang LH, et al. Scutellarin ameliorates osteoarthritis by protecting chondrocytes and subchondral bone microstructure by inactivating NF-κB/MAPK signal transduction. Biomed Pharmacother. 2022; 155:113781. https://doi.org/10.1016/j.biopha.2022.113781.

[82] Wan YP, Shen K, Yu HY, et al. Baicalein limits osteoarthritis development by inhibiting chondrocyte ferroptosis. Free Radic Biol Med. 2023; 196:108-120. https://doi.org/10.1016/j.freeradbiomed.2023.01.006.

[83] Sun K, Luo JH, Jing XZ, et al. Hyperoside ameliorates the progression of osteoarthritis: an in vitro and in vivo study. Phytomedicine. 2021; 80:153387. https://doi.org/10.1016/j.phymed.2020.153387.

[84] Lu R, He ZY, Zhang WK, et al. Oroxin B alleviates osteoarthritis through anti-inflammation and inhibition of PI3K/AKT/mTOR signaling pathway and enhancement of autophagy. Front Endocrinol (Lausanne). 2022; 13:1060721. https://doi.org/10.3389/fendo.2022.1060721.

[85] Wu WT, Chen YR, Lu DH, et al. Silymarin modulates catabolic cytokine expression through Sirt1 and SOX9 in human articular chondrocytes. J Orthop Surg Res. 2021; 16(1):147. https://doi.org/10.1186/s13018-021-02305-9.

[86] Gao Y, Wang SX, He L, et al. Alpinetin protects chondrocytes and exhibits anti-inflammatory effects via the NF-κB/ERK pathway for alleviating osteoarthritis. Inflammation. 2020; 43(5):1742-1750. https://doi.org/10.1007/s10753-020-01248-3.

[87] Kothari P, Tripathi AK, Girme A, et al. Caviunin glycoside (CAFG) from Dalbergia sissoo attenuates osteoarthritis by modulating chondrogenic and matrix regulating proteins. J Ethnopharmacol. 2022; 282:114315. https://doi.org/10.1016/j.jep.2021.114315.

[88] Qi WH, Chen YL, Sun SB, et al. InhibitingTLR4signalingbylinarinforpreventinginflammatoryresponseinosteoarthritis. Aging (Albany NY). 2021; 13(4):5369-5382. https://doi.org/10.18632/aging.202469.

[89] Lee SA, Park BR, Moon SM, et al. Chondroprotective effect of cynaroside in IL-1β-induced primary rat chondrocytes and organ explants via NF-κB and MAPK signaling inhibition. Oxid Med Cell Longev. 2020; 2020:9358080. https://doi.org/10.1155/2020/9358080.

[90] Yan ZJ, Lin Z, Wu YF, et al. The protective effect of myricitrin in osteoarthritis: an in vitro and in vivo study. Int Immunopharmacol. 2020; 84:106511. https://doi.org/10.1016/j.intimp.2020.106511.

[91] Xu Z, Shen ZH, Wu B, et al. Small molecule natural compound targets the NF-iB signaling and ameliorates the development of osteoarthritis. J Cell Physiol. 2021; 236(11):7298-7307. https://doi.org/10.1002/jcp.30392.

[92] Zhang J, Yin J, Zhao DH, et al. Therapeutic effect and mechanism of action of quercetin in a rat model of osteoarthritis. J Int Med Res. 2020; 48(3):300060519873461. https://doi.org/10.1177/0300060519873461.

[93] Liao WZ, Ning ZX, Chen LY, et al. Intracellular antioxidant detoxifying effects of diosmetin on 2,2-azobis(2-amidinopropane) dihydrochloride (AAPH)-induced oxidative stress through inhibition of reactive oxygen species generation. J Agric Food Chem. 2014; 62(34):8648-8654. https://doi.org/10.1021/jf502359x.

[94] Ding HZ, Ding H, Mu P, et al. Diosmetin inhibits subchondral bone loss and indirectly protects cartilage in a surgically-induced osteoarthritis mouse model. Chem Biol Interact. 2023; 370:110311. https://doi.org/10.1016/j.cbi.2022.110311.

[95] Qian L, Li C, Liu H, et al. Diosmetin ameliorates osteoarthritic inflammation in vivo and ECM macromolecules degradation in interleukin-1β-stimulated murine chondrocytes through the Nrf2/NF-κB pathway. Folia Histochem Cytobiol. 2024; 62(2):99-109. https://doi.org/10.5603/fhc.100071.

[96] Jia C, Hu F, Lu D, et al. Formononetin inhibits IL-1β-induced inflammation in human chondrocytes and slows the progression of osteoarthritis in rat model via the regulation of PTEN/AKT/NF-κB pathway. Int Immunopharmacol, 2022;113(Pt A):109309. https://doi.org/10.1016/j.intimp.2022.109309.

[97] Cho IA, Kim TH, Lim H, et al. Formononetin antagonizes the interleukin-1β-induced catabolic effects through suppressing inflammation in primary rat chondrocytes. Inflammation. 2019; 42(4):1426-1440. https://doi.org/10.1007/s10753-019-01005-1.

[98] Ni KN, Ye L, Zhang YJ, et al. Formononetin improves the inflammatory response and bone destruction in knee joint lesions by regulating the NF-κB and MAPK signaling pathways. Phytother Res. 2023; 37(8):3363-3379. https://doi.org/10.1002/ptr.7810.

[99] Fei JL, Liang B, Jiang CZ, et al. Luteolin inhibits IL-1β-induced inflammation in rat chondrocytes and attenuates osteoarthritis progression in a rat model. Biomed Pharmacother. 2019; 109:1586-1592. https://doi.org/10.1016/j.biopha.2018.09.161.

[100] Yang SC, Chen PJ, Chang SH, et al. Luteolin attenuates neutrophilic oxidative stress and inflammatory arthritis by inhibiting Raf1 activity. Biochem Pharmacol. 2018; 154:384-396. https://doi.org/10.1016/j.bcp.2018.06.003.

[101] Chu J, Yan B, Zhang J, et al. Casticin attenuates osteoarthritis-related cartilage degeneration by inhibiting the ROS-mediated NF-κB signaling pathway in vitro and in vivo. Inflammation. 2020; 43(3):810-820. https://doi.org/10.1007/s10753-019-01167-y.

[102] Li XC, Mei W, Huang ZQ, et al. Casticin suppresses monoiodoacetic acid-induced knee osteoarthritis through inhibiting HIF-1α/NLRP3 inflammasome signaling. Int Immunopharmacol. 2020; 86:106745. https://doi.org/10.1016/j.intimp.2020.106745.

[103] Liu DR, Mei W, Kang JF, et al. Casticin ameliorates osteoarthritic cartilage damage in rats through PI3K/AKT/HIF-1α signaling. Chem Biol Interact. 2024; 391:110897. https://doi.org/10.1016/j.cbi.2024.110897.

[104] Chen J, Wang C, Huang KM, et al. Acacetin suppresses IL-1β-induced expression of matrix metalloproteinases in chondrocytes and protects against osteoarthritis in a mouse model by inhibiting NF-κB signaling pathways. Biomed Res Int. 2020; 2020:2328401. https://doi.org/10.1155/2020/2328401.

[105] Xu DJ, Zhang LJ, Song CY, et al. Acacetin targets STING to alleviate the destabilization of the medial meniscus-induced osteoarthritis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):8863-8878. https://doi.org/10.1007/s00210-024-03167-8.

[106] Shi XQ, Jie LS, Wu P, et al. Calycosin mitigates chondrocyte inflammation and apoptosis by inhibiting the PI3K/AKT and NF-κB pathways. J Ethnopharmacol. 2022; 297:115536. https://doi.org/10.1016/j.jep.2022.115536.

[107] Su H, Yan QJ, Du W, et al. Calycosin ameliorates osteoarthritis by regulating the imbalance between chondrocyte synthesis and catabolism. BMC Complement Med Ther. 2024; 24(1):48. https://doi.org/10.1186/s12906-023-04314-z.

[108] Guo XY, Pan XH, Wu J, et al.Calycosin prevents IL-1β-induced articular chondrocyte damage in osteoarthritis through regulating the PI3K/AKT/FoxO1 pathway. In Vitro Cell Dev Biol Anim. 2022; 58(6):491-502. https://doi.org/10.1007/s11626-022-00694-7.

[109] Yang Y, Wang YW, Wang YM, et al. Tormentic acid inhibits IL-1β-induced inflammatory response in human osteoarthritic chondrocytes. Inflammation. 2016; 39(3):1151-1159. https://doi.org/10.1007/s10753-016-0349-8.

[110] Wang XZ, Liu ZL, Peng PJ, et al. Astaxanthin attenuates osteoarthritis progression via inhibiting ferroptosis and regulating mitochondrial function in chondrocytes. Chem Biol Interact. 2022; 366:110148. https://doi.org/10.1016/j.cbi.2022.110148.

[111] Sun JY, Song XJ, Wang CJ, et al. Geniposidic acid alleviates osteoarthritis progression through inhibiting inflammation and chondrocytes ferroptosis. J Cell Mol Med. 2024; 28(8):e18228. https://doi.org/10.1111/jcmm.18228.

[112] Liu B, Wu YL, Liang T, et al. Betulinic acid attenuates osteoarthritis via limiting NLRP3 inflammasome activation to decrease interleukin-1β maturation and secretion. Mediators Inflamm. 2023; 2023:3706421. https://doi.org/10.1155/2023/3706421.

[113] Huang JS, Chen ZX, Wu ZY, et al. Geniposide stimulates autophagy by activating the GLP-1R/AMPK/mTOR signaling in osteoarthritis chondrocytes. Biomed Pharmacother. 2023; 167:115595. https://doi.org/10.1016/j.biopha.2023.115595.

[114] Meng X, Sun LY, Meng XM, et al. The protective effect of ergolide in osteoarthritis: in vitro and in vivo studies. Int Immunopharmacol. 2024; 127:111355. https://doi.org/10.1016/j.intimp.2023.111355.

[115] Li J, Jiang MQ, Yu ZT, et al. Artemisinin relieves osteoarthritis by activating mitochondrial autophagy through reducing TNFSF11 expression and inhibiting PI3K/AKT/mTOR signaling in cartilage. Cell Mol Biol Lett. 2022; 27(1):62. https://doi.org/10.1186/s11658-022-00365-1.

[116] Jia LN, Gong YC, Jiang XR, et al. Ginkgolide C inhibits ROS-mediated activation of NLRP3 inflammasome in chondrocytes to ameliorate osteoarthritis. J Ethnopharmacol. 2024; 325:117887. https://doi.org/10.1016/j.jep.2024.117887.

[117] Xia TT, Zhao RZ, He SJ, et al. Gardenoside ameliorates inflammation and inhibits ECM degradation in IL-1β-treated rat chondrocytes via suppressing NF-κB signaling pathways. Biochem Biophys Res Commun. 2023; 640:164-172. https://doi.org/10.1016/j.bbrc.2022.12.016.

[118] Xu CM, Tang YC, Yang H, et al. Harpagide inhibits the TNF-α-induced inflammatory response in rat articular chondrocytes by the glycolytic pathways for alleviating osteoarthritis. Int Immunopharmacol. 2024; 127:111406. https://doi.org/10.1016/j.intimp.2023.111406.

[119] Hong X, Liu XQ, Li B, et al. Glaucocalyxin A delays the progression of OA by inhibiting NF-κB and MAPK signaling pathways. J Orthop Surg Res. 2024; 19(1):188. https://doi.org/10.1186/s13018-024-04640-z.

[120] Hu W, Mao C, Sheng WB. The protective effect of kirenol in osteoarthritis: an in vitro and in vivo study. J Orthop Surg Res. 2022; 17(1):195. https://doi.org/10.1186/s13018-022-03063-y.

[121] Jia T, Cai MM, Ma X, et al. Oridonin inhibits IL-1β-induced inflammation in human osteoarthritis chondrocytes by activating PPAR-γ. Int Immunopharmacol. 2019; 69:382-388. https://doi.org/10.1016/j.intimp.2019.01.049.

[122] He HB, Jiang H, Chen Y, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018; 9(1):2550. https://doi.org/10.1038/s41467-018-04947-6.

[123] Salman I, Fakhoury M, Fouani M, et al. Peripheral anti-nociceptive and anti-inflammatory effect of oleanolic acid in a rat model of osteoarthritis. Antiinflamm Antiallergy Agents Med Chem. 2021; 20(3):239-249. https://doi.org/10.2174/1871523019999201111191754.

[124] Bao JP, Yan WF, Xu K, et al. Oleanolic acid decreases IL-1β-induced activation of fibroblast-like synoviocytes via the SIRT3-NF-κB axis in osteoarthritis. Oxid Med Cell Longev. 2020; 2020:7517219. https://doi.org/10.1155/2020/7517219.

[125] Ma TW, Ruan HR, Lv LY, et al. Oleanolic acid, a small-molecule natural product, inhibits ECM degeneration in osteoarthritis by regulating the Hippo/YAP and Wnt/β-catenin pathways. Food Funct. 2023; 14(22):9999-10013. https://doi.org/10.1039/D3FO01902K.

[126] Li EQ, Zhang JL. Therapeutic effects of triptolide from Tripterygium wilfordii Hook. f. on interleukin-1β-induced osteoarthritis in rats. Eur J Pharmacol. 2020; 883:173341. https://doi.org/10.1016/j.ejphar.2020.173341.

[127] Liu G, Wang LJ, Tuerxunyiming M, et al. Triptolide ameliorates osteoarthritis by regulating nuclear factor kappa B-mediated inflammatory response. J Pharm Pharmacol. 2022;28:rgab182. https://doi.org/10.1093/jpp/rgab182.

[128] Qian KJ, Zhang L, Shi KQ. Triptolide prevents osteoarthritis via inhibiting hsa-miR-20b. Inflammopharmacology. 2019; 27(1):109-119. https://doi.org/10.1007/s10787-018-0509-6.

[129] Sun K, Luo JH, Jing XZ, et al.Astaxanthin protects against osteoarthritis via Nrf2:a guardian of cartilage homeostasis. Aging (Albany NY). 2019; 11(22):10513-10531. https://doi.org/10.18632/aging.102474.

[130] Hill WS, Dohnalek MH, Ha Y, et al. A multicenter, randomized, double-blinded, placebo-controlled clinical trial to evaluate the efficacy and safety of a krill oil, astaxanthin, and oral hyaluronic acid complex on joint health in people with mild osteoarthritis. Nutrients. 2024; 16(12):1961. https://doi.org/10.3390/nu16121961.

[131] Yao MJ, Zhang CH, Ni LZ, et al. Cepharanthine ameliorates chondrocytic inflammation and osteoarthritis via regulating the MAPK/NF-κB-autophagy pathway. Front Pharmacol. 2022; 13:854239. https://doi.org/10.3389/fphar.2022.854239.

[132] Kong XY, Ning C, Liang ZGN, et al. Koumine inhibits IL-1β-induced chondrocyte inflammation and ameliorates extracellular matrix degradation in osteoarthritic cartilage through activation of PINK1/Parkin-mediated mitochondrial autophagy. Biomed Pharmacother. 2024; 173:116273. https://doi.org/10.1016/j.biopha.2024.116273.

[133] Li M, Zhu Y, Shao JJ, et al. Chelidonine reduces IL-1β-induced inflammation and matrix catabolism in chondrocytes and attenuates cartilage degeneration and synovial inflammation in rats. Braz J Med Biol Res. 2023; 56:e12604. https://doi.org/10.1590/1414-431x2023e12604.

[134] Zhu MS, Xu Q, Yang XM, et al. Vindoline attenuates osteoarthritis progression through suppressing the NF-κB and ERK pathways in both chondrocytes and subchondral osteoclasts. Front Pharmacol. 2022; 12:764598. https://doi.org/10.3389/fphar.2021.764598.

[135] Fang YQ, Lou C, Lv JL, et al. Sipeimine ameliorates osteoarthritis progression by suppression of NLRP3 inflammasome-mediated pyroptosis through inhibition of PI3K/AKT/NF-κB pathway: an in vitro and in vivo study. J Orthop Translat. 2024; 46:1-17. https://doi.org/10.1016/j.jot.2024.04.004.

[136] Zhang Y, Liu WG, Liu ZH, et al. Daurisoline attenuates H₂O₂-induced chondrocyte autophagy by activating the PI3K/Akt/mTOR signaling pathway. J Orthop Surg Res. 2023; 18(1):248. https://doi.org/10.1186/s13018-023-03717-5.

[137] Zhou JY, Wu JT, Fu FD, et al. α-Solanine attenuates chondrocyte pyroptosis to improve osteoarthritis via suppressing NF-κB pathway. J Cell Mol Med. 2024; 28(4):e18132. https://doi.org/10.1111/jcmm.18132.

[138] Meng Y, Yin DZ, Qiu SQ, et al. Abrine promotes cell proliferation and inhibits apoptosis of interleukin-1β-stimulated chondrocytes via PIM2/VEGF signalling in osteoarthritis. Phytomedicine. 2022; 96:153906. https://doi.org/10.1016/j.phymed.2021.153906.

[139] Li SL, Shi YF, Zhang SH, et al. Corynoline alleviates osteoarthritis development via the Nrf2/NF-κB Pathway. Oxid Med Cell Longev. 2022; 2022:2188145. https://doi.org/10.1155/2022/2188145.

[140] Sha YQ, Zhang BB, Chen LP, et al. Dehydrocorydaline accelerates cell proliferation and extracellular matrix synthesis of TNFα-treated human chondrocytes by targeting COX2 through JAK1-STAT3 signaling pathway. Int J Mol Sci. 2022; 23(13):7268. https://doi.org/10.3390/ijms23137268.

[141] Chen HJ, Zhong YM, Sang WL, et al. Protopine protects chondrocytes from undergoing ferroptosis by activating Nrf2 pathway. Biochem Biophys Res Commun. 2024; 710:149599. https://doi.org/10.1016/j.bbrc.2024.149599.

[142] Xia GQ, Zhu MP, Li JW, et al. An alkaloid from Menispermum dauricum, dauricine mediates Ca²⁺ influx and inhibits NF-κB pathway to protect chondrocytes from IL-1β-induced inflammation and catabolism. J Ethnopharmacol. 2024; 321:117560. https://doi.org/10.1016/j.jep.2023.117560.

[143] Lin XX, Yuan GX, Yang B, et al. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity. Phytomedicine. 2024; 129:155559. https://doi.org/10.1016/j.phymed.2024.155559.

[144] Li ZY, Shi HS, Li YM, et al. Isorhynchophylline ameliorates the progression of osteoarthritis by inhibiting the NF-κB pathway. Eur J Pharmacol. 2022; 924:174971. https://doi.org/10.1016/j.ejphar.2022.174971.

[145] Jiang JY, Li J, Xiong CW, et al. Isorhynchophylline alleviates cartilage degeneration in osteoarthritis by activating autophagy of chondrocytes. J Orthop Surg Res. 2023; 18(1):154. https://doi.org/10.1186/s13018-023-03645-4.

[146] Zhou KL, Liu D, Jin YS, et al. Oxymatrine ameliorates osteoarthritis via the Nrf2/NF-κB axis in vitro and in vivo. Chem Biol Interact. 2023; 380:110539. https://doi.org/10.1016/j.cbi.2023.110539.

[147] Jiang YF, Sang WL, Wang C, et al. Oxymatrine exerts protective effects on osteoarthritis via modulating chondrocyte homoeostasis and suppressing osteoclastogenesis. J Cell Mol Med. 2018; 22(8):3941-3954. https://doi.org/10.1111/jcmm.13674.

[148] Lu JY, Bian J, Wang YT, et al. Oxymatrine protects articular chondrocytes from IL-1β-induced damage through autophagy activation via AKT/mTOR signaling pathway inhibition. J Orthop Surg Res. 2024; 19(1):178. https://doi.org/10.1186/s13018-024-04667-2.

[149] Wu YF, Lin Z, Yan ZJ, et al. Sinomenine contributes to the inhibition of the inflammatory response and the improvement of osteoarthritis in mouse-cartilage cells by acting on the Nrf2/HO-1 and NF-κB signaling pathways. Int Immunopharmacol. 2019; 75:105715. https://doi.org/10.1016/j.intimp.2019.105715.

[150] Dong HC, Li PN, Chen CJ, et al. Sinomenine attenuates cartilage degeneration by regulating miR-223-3p/NLRP3 inflammasome signaling. Inflammation. 2019; 42(4):1265-1275. https://doi.org/10.1007/s10753-019-00986-3.

[151] Zhang C, Li ZY, Li LH, et al. Achyranthoside D (AD) improve intervertebral disc degeneration through affect the autophagy and the activation of PI3K/Akt/mTOR pathway. J Orthop Surg (Hong Kong). 2022; 30(3):10225536221135474. https://doi.org/10.1177/10225536221135474.

[152] Xie WP, Qi SF, Dou LM, et al. Achyranthoside D attenuates chondrocyte loss and inflammation in osteoarthritis via targeted regulation of Wnt3a. Phytomedicine. 2023; 111:154663. https://doi.org/10.1016/j.phymed.2023.154663.

[153] Huang X, Shen QK, Guo HY, et al. Pharmacological overview of hederagenin and its derivatives. RSC Med Chem. 2023; 14(10):1858-1884. https://doi.org/10.1039/D3MD00296A.

[154] Shen Y, Teng L, Qu YH, et al. Hederagenin suppresses inflammation and cartilage degradation to ameliorate the progression of osteoarthritis: an in vivo and in vitro study. Inflammation. 2023; 46(2):655-678. https://doi.org/10.1007/s10753-022-01763-5.

[155] Wang NN, Xu PC, Wu RJ, et al. Timosaponin BII improved osteoporosis caused by hyperglycemia through promoting autophagy of osteoblasts via suppressing the mTOR/NF-κB signaling pathway. Free Radic Biol Med. 2021; 171:112-123. https://doi.org/10.1016/j.freeradbiomed.2021.05.014.

[156] Liu XW, Xiang DL, Jin WM, et al. Timosaponin B-II alleviates osteoarthritis-related inflammation and extracellular matrix degradation through inhibition of mitogen-activated protein kinases and nuclear factor-κB pathways in vitro. Bioengineered. 2022; 13(2):3450-3461. https://doi.org/10.1080/21655979.2021.2024685.

[157] Feng K, Ge YW, Chen ZX, et al. Curcumin inhibits the PERK-eIF2α-CHOP pathway through promoting SIRT1 expression in oxidative stress-induced rat chondrocytes and ameliorates osteoarthritis progression in a rat model. Oxid Med Cell Longev. 2019; 2019:8574386. https://doi.org/10.1155/2019/8574386.

[158] Zhang R, Zhang QX, Zou ZY, et al. Curcumin supplementation enhances bone marrow mesenchymal stem cells to promote the anabolism of articular chondrocytes and cartilage repair. Cell Transplant. 2021; 30:963689721993776. https://doi.org/10.1177/0963689721993776.

[159] Jin ZZ, Chang BH, Wei YL, et al. Curcumin exerts chondroprotective effects against osteoarthritis by promoting AMPK/PINK1/Parkin-mediated mitophagy. Biomed Pharmacother. 2022; 151:113092. https://doi.org/10.1016/j.biopha.2022.113092.

[160] Wang X, Yu HJ, Zhang YH, et al. Curcumin alleviates osteoarthritis through the p38MAPK pathway: network pharmacological prediction and experimental confirmation. J Inflamm Res. 2024; 17:5039-5056. https://doi.org/10.2147/JIR.S459867.

[161] Ding D, Liu GQ, Yan JB, et al. Curcumin alleviates osteoarthritis in mice by suppressing osteoclastogenesis in subchondral bone via inhibiting NF-κB/JNK signaling pathway. PLoS One. 2024; 19(9):e0309807. https://doi.org/10.1371/journal.pone.0309807.

[162] Jamali N, Adib-Hajbaghery M, Soleimani A. The effect of curcumin ointment on knee pain in older adults with osteoarthritis: a randomized placebo trial. BMC Complement Med Ther. 2020; 20(1):305. https://doi.org/10.1186/s12906-020-03105-0.

[163] Shep D, Khanwelkar C, Gade P, et al. Safety and efficacy of curcumin versus diclofenac in knee osteoarthritis: a randomized open-label parallel-arm study. Trials. 2019; 20(1):214. https://doi.org/10.1186/s13063-019-3327-2.

[164] Xiong GY, Yang YY, Guo MY. Effect of resveratrol on abnormal bone remodeling and angiogenesis of subchondral bone in osteoarthritis. Int J Clin Exp Pathol. 2021; 14(4):417-425.

[165] Wei YL, Jia J, Jin X, et al. Resveratrol ameliorates inflammatory damage and protects against osteoarthritis in a rat model of osteoarthritis. Mol Med Rep. 2018; 17(1):1493-1498. https://doi.org/10.3892/mmr.2017.8036.

[166] Wang J, Gao JS, Chen JW, et al. Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatol Int. 2012; 32(6):1541-1548. https://doi.org/10.1007/s00296-010-1720-y.

[167] Qin N, Wei LW, Li WY, et al. Local intra-articular injection of resveratrol delays cartilage degeneration in C57BL/6 mice by inducing autophagy via AMPK/mTOR pathway. J Pharmacol Sci. 2017; 134(3):166-174. https://doi.org/10.1016/j.jphs.2017.06.002.

[168] Hussain SA, Marouf BH, Ali ZS, et al. Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study. Clin Interv Aging. 2018; 13:1621-1630. https://doi.org/10.2147/CIA.S172758.

[169] Wong RHX, Evans HM, Howe PRC. Resveratrol supplementation reduces pain experience by postmenopausal women. Menopause. 2017; 24(8):916-922. https://doi.org/10.1097/GME.0000000000000861.

[170] Singh S, Jindal D, Khanna R. Can serum MMP-3 diagnose early knee osteoarthritis? J Orthop. 2023; 38:42-46. https://doi.org/10.1016/j.jor.2023.02.014.

[171] Singh S, Jindal D, Khanna R. sCTX II is a better biomarker than sMMP-3 to identify early knee osteoarthritis. J Orthop Res. 2023; 41(11):2455-2461. https://doi.org/10.1002/jor.25582.

[172] Li W, Du C, Wang H, et al. Increased serum ADAMTS-4 in knee osteoarthritis: a potential indicator for the diagnosis of osteoarthritis in early stages. Genet Mol Res. 2014; 13(4):9642-9649. https://doi.org/10.4238/2014.November.14.9.

[173] Boffa A, Merli G, Andriolo L, et al. Synovial fluid biomarkers in knee osteoarthritis: a systematic review and quantitative evaluation using BIPEDs criteria. Cartilage. 2021; 13(1_suppl):82S-103S. https://doi.org/10.1177/1947603520942941.

[174] Monibi F, Roller BL, Stoker A, et al. Identification of synovial fluid biomarkers for knee osteoarthritis and correlation with radiographic assessment. J Knee Surg. 2016; 29(3):242-247. https://doi.org/10.1055/s-0035-1549022.

[175] Petersen KK, Siebuhr AS, Graven-Nielsen T, et al. Sensitization and serological biomarkers in knee osteoarthritis patients with different degrees of synovitis. Clin J Pain. 2016; 32(10):841-848. https://doi.org/10.1097/AJP.0000000000000334.

[176] Fang SZ, Zhang B, Xiang W, et al. Natural products in osteoarthritis treatment: bridging basic research to clinical applications. Chin Med. 2024; 19(1):25. https://doi.org/10.1186/s13020-024-00899-w.

[177] Feng YZ, Pan M, Li R, et al. Recent developments and new directions in the use of natural products for the treatment of inflammatory bowel disease. Phytomedicine. 2024; 132:155812. https://doi.org/10.1016/j.phymed.2024.155812.

[178] Dei Cas M, Ghidoni R. Dietary curcumin: correlation between bioavailability and health potential. Nutrients. 2019; 11(9):2147. https://doi.org/10.3390/nu11092147.

[179] Liu YY, Ma ZY, Wang X, et al. A core-brush nanoplatform with enhanced lubrication and anti-inflammatory properties for osteoarthritis treatment. Adv Sci (Weinh). 2024; 11(47):e2406027. https://doi.org/10.1002/advs.202406027.